Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632532 | 0.77 | CHEK1 (0.43) | CHEK1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL19646489 | 0.77 | CHEK1 (0.42) | CHEK1POLBPDE5APDE1APDE1B | |
| SCHEMBL17403218 | 0.77 | CHEK1 (0.42) | CHEK1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL15886682 | 0.73 | CHEK1 (0.49) | CHEK1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL20996080 | 0.73 | CHEK1 (0.39) | CHEK1KDM4EPDE5APDE1APDE1B | |
| SCHEMBL18632524 | 0.73 | PDE3B (0.47) | CHEK1CYP1A2PDE5APDE1APDE1B | |
| SCHEMBL5470280 | 0.72 | CHEK1 (0.67) | CHEK1 | |
| SCHEMBL19584030 | 0.72 | CHEK1 (0.38) | CHEK1CYP1A2KDM4EALDH1A1POLB | |
| SCHEMBL15995871 | 0.70 | CHEK1 (0.43) | CHEK1PDE5APDE1APDE1BPDE3B | |
| SCHEMBL21034104 | 0.68 | CHEK1 (0.35) | CHEK1CYP1A2PDE5APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| US-9827244-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-9771351-B2 | Wnt signaling inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9771351-B2 | Wnt signaling inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-01-05 | — | — | US | disclosed |
| US-20160168125-A1 | WNT SIGNALING INHIBITOR | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168125-A1 | WNT SIGNALING INHIBITOR | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3028703-A1 | Wnt SIGNALING INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| WO-2016005330-A1 | DIHYDROPYRIDOPYRAZINE-1,8-DIONES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-14 | — | — | WO | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
| WO-2015016195-A1 | Wnt SIGNALING INHIBITOR | 協和発酵キリン株式会社 (JP) | 2015-02-05 | — | — | WO | disclosed |
| US-4465683-A | TRIAZOLOPYRIDINONES | MEAD JOHNSON & COMPANY (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0025985-B1 | 2-SUBSTITUTED TRIAZOLO(4,3-1)PYRIDIN-3(2H)-ONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DEPRESSION | Bristol-Myers Company (US) | 1983-11-23 | — | — | EP | disclosed |
| EP-0025603-B1 | TRIAZOLO (4,3-A)PYRIDIN-3(2H)-ONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Bristol-Myers Company (US) | 1983-11-02 | — | — | EP | disclosed |
| EP-0025985-A1 | 2-Substituted triazolo(4,3-1)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions for the treatment of depression | Bristol-Myers Company (US) | 1981-04-01 | — | — | EP | disclosed |
| EP-0025603-A1 | Triazolo (4,3-a)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions containing them | Bristol-Myers Company (US) | 1981-03-25 | — | — | EP | disclosed |
| US-4254124-A | 2-(3-(4-(TRIFLUOROMETHYLPHENYL)-PIPERAZINO)-PROPYL)-S-TRIAZOLO(4,3 -A)PYRIDIN-3-ONE | MEAD JOHNSON & COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | CHEK1 3729/4885HTT 3665/4885CYP1A2 715/4885 |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | MME, CAPRIN1, XPNPEP1 | CHEK1 3715/4885HTT 3142/4885CYP1A2 949/4885 |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | MME, CAPRIN1, XPNPEP1 | CHEK1 3715/4885HTT 3142/4885CYP1A2 949/4885 |
| US-20160168125-A1 | WNT SIGNALING INHIBITOR | WNT3A, WNT1, WNT3 | CHEK1 2689/4885HTT 4416/4885CYP1A2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.